[Treatment with bromperidol in schizophrenic patients].
The antipsychotic action, and undesirable effects of Bromperidol were examined over a 3-month period on an open clinical trial with 33 schizophrenic patients. Bromperidol was administered at an initial dose of 2.5 to 10 mg once a day. The results obtained according to BPRS and CGI parameters after 2 weeks' time, and 1, 2, and 3 months' time showed a marked improvement in most of the scored psychiatric symptoms. Bromperidol has a potent antipsychotic action and some stimulating properties on activity which make it very useful when increasing patients' motivation, and resocialization is at stake. Its general tolerance was very good. Nine patients (27%) presented mild extrapyramidal side-effects which were easily controlled with an anticholinergic medication.
Ellerman
L A
LA
Hospital Zonal, Rosario del Tala, Argentina.
D000293:Adolescent; D000328:Adult; D005260:Female; D006220:Haloperidol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy*; D012562:Schizophrenia, Disorganized / Q000188:drug therapy; D012563:Schizophrenia, Paranoid / Q000188:drug therapy
D006220:Haloperidol; C006820:bromperidol
Tratamiento con bromperidol en pacientes esquizofrénicos.